IBTM

IBTM (Institute of Biotechnology and Translational Medicine) is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of recombinant human proteins and biopharmaceuticals. The company's lead program, IBTM-001, is a recombinant human serum albumin (rHSA) produced using a proprietary yeast-based expression system, currently being evaluated in Phase 2 clinical trials for the treatment of hypoalbuminemia and liver cirrhosis. IBTM leverages advanced protein engineering and large-scale fermentation technologies to provide high-purity, animal-free alternatives to plasma-derived products. Its pipeline also includes recombinant human growth hormone and other therapeutic proteins aimed at addressing significant unmet medical needs in hepatology and endocrinology.